NCT03153410 2025-01-09Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the PancreasSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase EARLY_PHASE1 Completed11 enrolled 14 charts